PIPELINE

Nirsum has developed a series of novel small molecule candidates with potential utility in OUD. Our most advanced compounds NRS-033 for semi-annual dosing and NRS-067 for quarterly dosing are in preparation for IND-enabling toxicology. Nirsum retains 100% ownership of its compounds.